Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma

Drug Resistance Updates

Volumn 2, Issue 1, 1999, Pages 30-37

  Nagane, Motoo ^a   Huang, H J Su ^a,b   Cavenee, Webster K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLOROETHYLNITROSOUREA; CISPLATIN; CYTARABINE; DOXORUBICIN; GLYCOPROTEIN P; LOMUSTINE; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; NIMUSTINE; PACLITAXEL; PROCARBAZINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; TYROSINE KINASE RECEPTOR; VALSPODAR; VINBLASTINE;

ANGIOGENESIS; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033081691     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1998.0062     Document Type: Article

References (67)

1. Feun L. G., Savaraj N., Landy H. J. Drug resistance in brain tumors. J Neurooncol. 20:1994;165-176.
2. Phillips P. C. Antineoplastic drug resistance in brain tumors. Neurol Clin. 9:1991;383-404.
3. Takakura K., Abe H., Tanaka R. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg. 64:1986;53-57.
4. Barret J. M., Hill B. T. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs. 9:1998;105-123.
5. Erickson L., Laurent G., Sharkey N., Kohn K. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumor cells. Nature (Lond.). 288:1980;727-729.
6. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58:1998;1068-1073.
7. Belanich M., Pastor M., Randall T. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56:1996;783-788.
8. Chen Z. P., McQuillan A., Mohr G., Panasci L. C. Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery. 42:1998;1112-1119.
9. 6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery. 41:1997;434-440; discussion 440-441.
10. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res. 3:1997;837-847.
11. 6 -benzylguanine derivatives. Biochem Pharmacol. 53:1997;1559-1564.
12. 6 -benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci U S A. 93:1996;14088-14093.
13. El-Deiry W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol. 9:1997;79-87.
14. Land caspase-3-like proteases. Proc Natl Acad Sci U S A. 95:1998;5724-5729.
15. Disis M. L., Cheever M. A. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 71:1997;343-371.
16. Amarante M. G., McGahon A. J., Nishioka W. K., Afar D. E., Witte O. N., Green D. R. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 16:1998;1383-1390.
17. Tsai C. M., Levitzki A., Wu L. H. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56:1996;1068-1074.
18. Zhang L., Hung M. C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene. 12:1996;571-576.
19. Baselga J., Norton L., Albanell J., Kim Y. M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
20. Pegram M. D., Lipton A., Hayes D. F. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:1998;2659-2671.
21. Shen L., Glazer R. I. Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding protein-3. Biochem Pharmacol. 55:1998;1711-1719.
22. Huang P. S., Heimbrook D. C. Oncogene products as therapeutic targets for cancer. Curr Opin Oncol. 9:1997;94-100.
23. Gorospe M., Cirielli C., Wang X., Seth P., Capogrossi M. C., Holbrook N. J. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene. 14:1997;929-935.
24. Jung J. M., Bruner J. M., Ruan S. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 11:1995;2021-2028.
25. Waldman T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
26. Ruan S., Okcu M. F., Ren J. P. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res. 58:1998;1538-1543.
27. Hama S., Heike Y., Naruse I. Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer. 77:1998;47-54.
28. Ruley H. E. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol. 1996:1996;37-56.
29. Iwadate Y., Fujimoto S., Tagawa M. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer. 69:1996;236-240.
30. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292:1998;435-445.
31. Gjerset R. A., Turla S. T., Sobol R. E. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog. 14:1995;275-285.
32. Kondo S., Barnett G. H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene. 10:1995;2001-2006.
33. Reed J. C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 7:1995;541-546.
34. Weller M., Malipiero U., Aguzzi A., Reed J. C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
35. Kitada S., Takayama S., De Riel K., Tanaka S., Reed J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. 4:1994;71-79.
36. Jansen B., Schlagbauer W. H., Brown B. D. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 4:1998;232-234.
37. Rieger L., Weller M., Bornemann A., Schabet M., Dichgans J., Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci. 155:1998;68-75.
38. Krishna M., Smith T. W., Recht L. D. Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg. 83:1995;1017-1022.
39. Weller, M. Kleihues, P. Dichgans, J. Ohgaki, H. CD95 ligand: lethal weapon against malignant glioma? Brain Pathol, 1998, 8, 285-293.
40. Rieger, J. Naumann, U. Glaser, T. Ashkenazi, A. Weller, M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett, 1998;427:124-128.
41. Weller M., Malipiero U., Rensing E. A., Barr P. J., Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2936-2944.
42. Roth W., Fontana A., Trepel M., Reed J. C., Dichgans J., Weller M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother. 44:1997;55-63.
43. Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 7:1997;R750-753.
44. Kondo S., Tanaka Y., Kondo Y. Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res. 58:1998;962-967.
45. Kroll R. A., Neuwelt E. A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 42:1998;1083-1099; discussion 1099-1100.
46. Tatsuta T., Naito M., Ohhara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem. 267:1992;20383-20391.
47. Schinkel A. H., Smit J. J., van Tellingen O. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
48. Nomura T., Inamura T., Black K. L. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 659:1994;62-66.
49. Sugita M., Black K. L. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res. 58:1998;914-920.
50. Toth K., Vaughan M. M., Peress N. S., Slocum H. K., Rustum Y. M. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol. 149:1996;853-858.
51. von Bossanyi P., Diete S., Dietzmann K., Warich Kirches M., Kirches E. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl). 94:1997;605-611.
52. Mayer U., Wagenaar E., Dorobek B., Beijnen J. H., Borst P., Schinkel A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 100:1997;2430-2436.
53. Huai Y. H., Secrest D. T., Mark K. S. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun. 243:1998;816-820.
54. Kusuhara H., Suzuki H., Naito M., Tsuruo T., Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther. 285:1998;1260-1265.
55. Regina A., Koman A., Piciotti M. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem. 71:1998;705-715.
56. Brem H., Piantadosi S., Burger P. C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 345:1995;1008-1012.
57. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 175:1972;409-416.
58. Boehm T., Folkman J., Browder T., O'Reilly M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
59. O'Reilly M. S., Holmgren L., Shing Y. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
60. O'Reilly M. S., Boehm T., Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
61. Griscelli F., Li H., Bennaceur G. A. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A. 95:1998;6367-6372.
62. Tanaka T., Cao Y., Folkman J., Fine H. A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58:1998;3362-3369.
63. Mauceri H. J., Hanna N. N., Beckett M. A. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:1998;287-291.
64. Cheng S. Y., Huang H. J. S., Nagane M. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 93:1996;8502-8507.
65. Goldman C. K., Kendall R. L., Cabrera G. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 95:1998;8795-8800.
66. Lin P., Buxton J. A., Acheson A. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A. 95:1998;8829-8834.
67. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.